Nuvectis Pharma, Inc.

NASDAQ:NVCT

Biotechnology

Healthcare
$19.84 +3.06%

+$0.39 today

Market cap
$682.28M
Beta
-0.07
P/E (TTM)
-11.2
EPS (TTM)
-$1.16
52W Low $5.55High $13.51

Volume 0.16M

Average 0.08M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$27.57M

FY 2025 · Annual

Net Income

-$26.44M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development9.55M13.23M15.38M12.92M18.15M
Selling, General & Admin3.35M6.01M7.52M6.93M9.42M
Operating Expenses12.89M19.23M22.9M19.85M27.57M
Depreciation & Amortization00000
EBITDA(12.89M)(19.09M)(22.26M)(19M)(26.44M)
EBITDA Margin—————
Operating Income(12.89M)(19.23M)(22.9M)(19.85M)(27.57M)
Operating Margin—————
Interest Income4K149K637K847K1.13M
Interest Expense00000
Other Income / Expenses4K149K637K847K1.13M
Income Before Tax(12.89M)(19.09M)(22.26M)(19M)(26.44M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.89M)(19.09M)(22.26M)(19M)(26.44M)
Net Margin—————
EPS (Basic)(1.09)(1.51)(1.43)(1.11)(1.32)
EPS (Diluted)(1.09)(1.51)(1.43)(1.11)(1.32)
Weighted Avg Shares12.72M12.66M15.56M17.11M21.81M
Weighted Avg Shares (Diluted)12.72M12.66M15.56M17.11M21.81M

NVCT Earnings Waterfall · TTM

NASDAQ:NVCT · Revenue to Net Income

Key Ratios

EPS$-1.31
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.0
P/S Ratio0.0

Analysis

$0 of revenue converted into -$27.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.31, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
EFFECTEFFECT filingAug 28, 2026
S-3S-3 filingAug 21, 2026
8-KCurrent reportAug 21, 2026

How much revenue does NVCT generate?

Nuvectis Pharma, Inc. (NVCT) reported $0.00 of revenue in fiscal 2025.

Is NVCT profitable?

Nuvectis Pharma, Inc. (NVCT) reported -$26.44M of net income.